Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$0.22
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-3.9M · quality 57.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$113M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-9.8%
↓Gross Margin
62.8%
↑Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.7%
FCF CAGR
—
FCF margin
-13.8%
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $28.3M · net income $-5.0M · FCF $-3.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $28.3M | $28.3M | $25.4M | $24.6M | $25.3M |
| Net Income | $-5.0M | $-5.0M | $-4.2M | $-5.8M | $-3.1M |
| EBITDA | $-1.1M | $-1.1M | $-738000.00 | $-2.5M | $188000.00 |
| EPS | — | — | -0.01 | -0.01 | -0.01 |
| Gross Margin | 62.8% | 62.8% | 67.3% | 65.3% | 66.8% |
| Operating Margin | -27.6% | -27.6% | -19.3% | -26.3% | -17.2% |
| Net Margin | -17.7% | -17.7% | -16.4% | -23.5% | -12.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.02 | 0.10 | 0.03 |
| Current Ratio | 3.88 | 3.88 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.9M | $-3.9M | $-5.1M | $-1.6M | $475000.00 |
| Returns | |||||
| ROE | -9.8% | -9.8% | -7.7% | -11.3% | -5.4% |
| Valuation | |||||
| EV/EBITDA | — | — | — | — | 241.78 |
| P/B | 2.22 | 2.22 | 1.44 | 1.11 | 1.36 |
| Growth & Yield | |||||
| Revenue Growth | 11.5% | 11.5% | 3.0% | -2.8% | — |
| EPS Growth | — | — | 38.1% | -82.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-45.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → n/d
Residual
-45.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.